Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Ends Deal For Anacor’s Antibiotic, Returns Rights

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharma ended the deal after halting studies on an antibiotic for Gram-negative bacterial infections when some clinical patients showed evidence of microbiological resistance.

You may also be interested in...



Anacor’s Tavaborole May Lag Valeant’s Competing Antifungal In Both Efficacy And Approval Time

Anacor released positive top-line Phase III data for the most advanced of its boron-based anti-infectives, the antifungal tavaborole, but the results weren’t good enough for some shareholders who were looking for the compound to best Valeant’s antifungal, currently pending at FDA with a May action date.

Anacor’s Tavaborole May Lag Valeant’s Competing Antifungal In Both Efficacy And Approval Time

Anacor released positive top-line Phase III data for the most advanced of its boron-based anti-infectives, the antifungal tavaborole, but the results weren’t good enough for some shareholders who were looking for the compound to best Valeant’s antifungal, currently pending at FDA with a May action date.

Novel Antibiotics At ICAAC Spur Optimism On Resistance Front

While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS073466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel